Tasigna 150 mg Capsule

Tasigna 150 mg Capsule contains nilotinib, a targeted anticancer medicine used for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It works by blocking the BCR-ABL tyrosine kinase protein that supports the growth of abnormal leukemia cells. The hard capsule is taken orally under the supervision of a qualified healthcare professional.

BUY NOW

Category Novartis Healthcare Pvt Ltd

Description

Tasigna 150 mg contains 150 mg of nilotinib as nilotinib hydrochloride monohydrate. It is indicated for certain adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia, including newly diagnosed chronic-phase disease and cases resistant or intolerant to previous therapy. The capsule should be swallowed whole with water and taken without food according to the prescribed dosing schedule. Treatment should be initiated and monitored by a physician experienced in the diagnosis and management of CML.

Technical Specification

Specification	Details
Active Ingredient	Nilotinib 150 mg
Dosage Form	Hard Capsule
Therapeutic Class	Tyrosine Kinase Inhibitor
Main Indication	Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Capsule Size	Size 1
Storage	Do not store above 30°C

Product Also Known As

Tasigna 150 mg, Tasigna Nilotinib 150 mg Capsule, Nilotinib 150 mg Capsule, Nilotinib Hard Capsule, Tasigna Oncology Capsule, Nilotinib CML Capsule